Contrasting AstraZeneca (NASDAQ:AZN) and Oncotelic Therapeutics (OTCMKTS:OTLC)

AstraZeneca (NASDAQ:AZNGet Free Report) and Oncotelic Therapeutics (OTCMKTS:OTLCGet Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Institutional and Insider Ownership

15.7% of AstraZeneca shares are held by institutional investors. 39.2% of Oncotelic Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares AstraZeneca and Oncotelic Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AstraZeneca $44.35 billion 4.66 $3.29 billion $1.90 35.07
Oncotelic Therapeutics N/A N/A $5.09 million N/A N/A

AstraZeneca has higher revenue and earnings than Oncotelic Therapeutics.

Profitability

This table compares AstraZeneca and Oncotelic Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AstraZeneca 13.10% 30.30% 11.58%
Oncotelic Therapeutics N/A -83.41% -38.88%

Risk & Volatility

AstraZeneca has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, Oncotelic Therapeutics has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for AstraZeneca and Oncotelic Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AstraZeneca 0 3 3 0 2.50
Oncotelic Therapeutics 0 0 0 0 N/A

AstraZeneca presently has a consensus target price of $80.00, suggesting a potential upside of 20.05%. Given AstraZeneca’s higher probable upside, analysts clearly believe AstraZeneca is more favorable than Oncotelic Therapeutics.

Summary

AstraZeneca beats Oncotelic Therapeutics on 9 of the 10 factors compared between the two stocks.

About AstraZeneca

(Get Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

About Oncotelic Therapeutics

(Get Free Report)

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.